http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Zealand Pharma grants new warrants under employee warrant program
-
Zealand Pharma to attend Kempen Life Sciences Conference
-
Zealand Pharma (ZEAL) Names Emmanuel Dulac CEO
-
Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
-
Zealand Pharma announces Emmanuel Dulac as new CEO
-
Zealand Pharma announces Emmanuel Dulac as new CEO
-
Zealand Pharma to attend Needham Healthcare Conference
-
Total number of shares and voting rights in Zealand Pharma at March 31, 2019
-
Zealand Pharma increases its share capital as a consequence of a new issue of shares
-
Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
-
Zealand Pharma announces full-year 2018 results, strong cash position to support pipeline progress
-
Zealand Pharma announces full-year 2018 results, strong cash position to support pipeline progress
-
Zealand Pharma (ZEAL) Reports First Patient Dosing in Phase 3 Trial with Dasiglucagon for Treatment of Congenital Hyperinsulinism
-
Zealand Pharma doses first patient in Phase 3 trial with dasiglucagon for the treatment of congenital hyperinsulinism
-
Zealand Pharma announces registration of executive management and an update of the Articles of Association
-
Pharm-Olam Enrolls Patients in Zealand Pharma Orphan Drug Study
-
Zealand Pharma to attend JP Morgan Healthcare Conference and Oddo BHF Forum
-
Zealand Pharma completes equity investment in strategic partner Beta Bionics
-
Total number of shares and voting rights in Zealand Pharma at December 31, 2018
-
Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
-
Financial calendar for Zealand Pharma in 2019
-
Zealand Pharma (ZEAL) CEO Britt Meelby Jensen to Resign
-
Zealand Pharma announces change in Executive Management
-
Zealand Pharma - Interim report for the first nine months of 2018
-
Zealand Pharma - Interim report for the first nine months of 2018
-
Zealand Pharma to attend Jefferies and Bryan, Garnier & Co Healthcare Conferences
-
Zealand hosts conference call on November 15 at 4 pm CET (10 am EST) to present third quarter results for 2018
-
Zealand Pharma (ZEAL) Reports First Patient Enrollment in Phase 3 trial with Glepaglutide for treatment of SBS
-
Zealand Pharma enrolls first patient in Phase 3 trial with glepaglutide for the treatment of short bowel syndrome
-
Zealand Pharma enrolls first patient in Phase 3 trial with glepaglutide for the treatment of short bowel syndrome
-
Zealand Pharma expands leadership team and appoints Marino Garcia as Senior Vice President of Corporate & Business Development
-
Zealand Pharma expands leadership team and appoints Marino Garcia as Senior Vice President of Corporate & Business Development
-
Zealand Pharma (ZEAL) initiated the Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia in children
-
Zealand Pharma has initiated the Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia in children
-
Zealand Pharma has initiated the Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia in children
-
Zealand Pharma (ZEAL) Says it Achieves Primary and key Secondary Endpoints in Phase 3 Trial with Dasiglucagon for Severe Hypoglycemia
-
Zealand Pharma achieves primary and key secondary endpoints in pivotal Phase 3 trial with dasiglucagon for severe hypoglycemia
-
Zealand Pharma achieves primary and key secondary endpoints in pivotal Phase 3 trial with dasiglucagon for severe hypoglycemia
-
Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
-
Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
-
Zealand Pharma to attend J.P. Morgan Cazenove and Morgan Stanley Global Healthcare Conferences
-
Zealand Pharma (ZEAL) Reports Sale of Royalty Streams & Milestones to Royalty Pharma for $205M
-
Zealand sells royalty streams and milestones for USD 205 million to Royalty Pharma
-
Zealand sells royalty streams and milestones for USD 205 million to Royalty Pharma
-
Zealand Pharma - Interim report for the first half of 2018
-
Zealand hosts conference call on August 16 at 4 pm CET/10 am EDT to present first half of 2018 results
-
Zealand announces an 85% increase in Soliqua® 100/33/ Suliqua® royalty revenue from first to second quarter of 2018
-
Zealand Pharma major shareholder announcement: Van Herk Investments
-
Zealand Pharma presents two dasiglucagon milestone studies at the 78th Scientific Sessions of the American Diabetes Association (ADA)
-
Survey demonstrating underuse of glucagon rescue kits in type 1 diabetes patients to be presented at the ADA's 78th Scientific Sessions

